Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Allogene Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 182 | 2 | 169 | −11 |
| Shares | 86.3M | 635 | 88.0M | +1.63M (+1.9%) |
| Value | $2.25B | $17.0K | $2.26B | +$9.63M (+0.4%) |
2 institutions that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (18)
Institutions that held Allogene Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Capital Group Private Client Services, Inc. | 175,157 | $4.50M | 0.05% |
| Man Group plc | 52,572 | $1.35M | 0.00% |
| Ergoteles LLC | 50,483 | $1.30M | 0.05% |
| Jane Street Group, LLC | 15,354 | $395.0K | 0.00% |
| Copernicus Capital Management, LLC | 15,000 | $386.0K | 4.67% |
| Rothschild Investment Corp | 12,800 | $329.0K | 0.03% |
| Bailard, Inc. | 11,700 | $301.0K | 0.01% |
| Rockefeller Capital Management L.P. | 10,000 | $257.0K | 0.00% |
| Calton & Associates, Inc. | 9,546 | $245.0K | 0.05% |
| Algert Global LLC | 9,230 | $237.0K | 0.03% |
| Janus Henderson Group PLC | 7,795 | $200.0K | 0.00% |
| Alpha Paradigm Partners, LLC | 4,966 | $128.0K | 0.05% |
| Northwestern Mutual Wealth Management Co | 1,000 | $26.0K | 0.00% |
| Koshinski Asset Management, Inc. | 500 | $12.8K | 0.00% |
| Total Clarity Wealth Management, Inc. | 230 | $6.00K | 0.00% |
| TCI Wealth Advisors, Inc. | 192 | $5.00K | 0.00% |
| Bell Investment Advisors, Inc | 88 | $2.00K | 0.00% |
| Gerber Kawasaki Wealth & Investment Management | 10 | $0 | 0.00% |
Sold out (29)
Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
Not filed for Q3 2021 yet (2)
Institutions that held Allogene Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Elmwood Wealth Management, Inc. | 575 | $15.0K |
| Smith Asset Management Group LP | 60 | $2.00K |